Filing Flows › Gilead Sciences (GILD) › Free cash flow
Gilead Sciences (GILD) free cash flow by quarter
Gilead Sciences' free cash flow was $4.8B in Q3 2026 (third quarter 2026), +40% from Q2 2026. Over the last 7 quarters it ranged from $720M (Q2 2025) to $4.8B (Q3 2026).
| Quarter | Free cash flow | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $4.8B | +40% | +21% |
| Q2 2026 | $3.4B | +41% | +377% |
| Q1 2026 | $2.4B | -22% | +47% |
| Q4 2025 | $3.1B | -21% | — |
| Q3 2025 | $4.0B | +450% | — |
| Q2 2025 | $720M | -56% | — |
| Q1 2025 | $1.7B | — | — |
Q3 2026 at a glance
Gilead Sciences, Q3 2026: revenue $8.3B (+7% year over year), operating margin 41.7%, net earnings $2.4B, operating cash flow $5.0B. The chart follows the revenue to costs, profit and cash.
Questions
What is Gilead Sciences' free cash flow?
Gilead Sciences' free cash flow was $4.8B in Q3 2026 (third quarter 2026), +40% from Q2 2026.
How has Gilead Sciences' free cash flow changed?
Over the last 7 quarters it ranged from $720M (Q2 2025) to $4.8B (Q3 2026).